Aino Health (AINO) Q2 2025 earnings summary

Executive summary

• Revenue increased by 20% year-over-year in Q2 2025, reflecting continued growth and improved operational efficiency.

• Positive EBITDA achieved in Q2 2025, indicating underlying business strength.

• Strategic price adjustments led to some customer churn but supported long-term profitability.

• New customer signings and platform rollouts gained momentum, especially in manufacturing.

• Recurring revenue base strengthened, with stable cash flow and disciplined cost management.

Financial highlights

• Q2 2025 turnover was 7,471 TSEK, up from 6,236 TSEK in Q2 2024; H1 2025 turnover reached 14,848 TSEK, up from 12,230 TSEK.

• Profit after financial items improved to -587 TSEK in Q2 2025 from -2,017 TSEK in Q2 2024; H1 2025 was -1,141 TSEK versus -4,960 TSEK year-over-year.

• Operating result for Q2 2025 was -341 TSEK, compared to -1,767 TSEK in Q2 2024.

• Cash flow for Q2 2025 was -267 TSEK, compared to -502 TSEK in Q2 2024.

• Earnings per share for H1 2025 was -0.0 SEK, compared to -0.1 SEK in H1 2024.

Outlook and guidance

• Management expects continued profitable growth in 2025, supported by a solid pipeline and expanding market demand.

• Focus remains on innovation, customer success, and measurable health outcomes.